Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Annovis Bio (DE:07X)
FRANKFURT:07X
Holding DE:07X?
Track your performance easily
07X Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.42 - €18.10
Previous Close€8.3
Volume0.00
Average Volume (3M)2.25K
Market Cap
€103.96M
Enterprise Value€100.31M
Total Cash (Recent Filing)$4.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Nov 06, 2024EPS Estimate
-€0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,054,018
10 Day Avg. Volume0
30 Day Avg. Volume2,245
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-60.54
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.29
Forecast
1Y Price Target
€23.69Price Target Upside185.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Annovis Bio News
PremiumCompany Announcements
Annovis Bio Files Patents for Neurodegenerative Combination Therapies
Bulls Say, Bears Say
Bulls Say
Innovative Combination TherapiesRecent preclinical studies have shown that when buntanetap is combined with a GLP-1 agonist or PDE5 inhibitors, cognitive function in Alzheimer’s mouse models improves to levels beyond those observed in healthy controls.
Intellectual Property StrengtheningThe company has filed a new composition of matter patent for a novel crystal form of buntanetap, which offers improved properties such as enhanced solubility and stability, further strengthening its IP portfolio by extending the patent protection by an additional 20 years.
Regulatory ApprovalFDA granted clearance to Annovis Bio to proceed with pivotal Phase 3 studies of its lead candidate buntanetap.
Bears Say
Financial NeedsAnnovis Bio shall need to identify additional sources of capital in order to complete clinical development.
Financial PerformanceAnnovis filed its 10-Q reporting 2Q24 results with a net loss of ($5.0M) and ended the period with ~$4.0M in cash on the balance sheet.
Regulatory And Clinical ChallengesThe company characterized the potential filing of a new drug application (NDA) in PD as 'aggressive,' suggesting an alternate path involving a new 18-month Phase 3 study.
---
Options Prices
Currently, No data available
---
Ownership Overview
25.93% Insiders
3.43% Mutual Funds
0.36% Other Institutional Investors
67.26% Public Companies and
Individual Investors
07X FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was €4.42 and its highest was €18.10 in the past 12 months.
What is Annovis Bio’s market cap?
Currently, no data Available
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is Nov 06, 2024 which is in 18 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Aug 15, 2024. The company reported -€0.402 earnings per share for the quarter, beating the consensus estimate of -€0.574 by €0.172.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate is -€0.47.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 13,054,018 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -€0.402 in its last earnings report, beating expectations of -€0.574. Following the earnings report the stock price went down -1.821%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in DE:07X
---
Annovis Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€23.69 (185.45% Upside)
€23.69 (185.45% Upside)
Blogger Sentiment
Bullish
DE:07X Sentiment 86%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.14%
12-Months-Change
Fundamentals
Return on Equity
-453.01%
Trailing 12-Months
Asset Growth
-77.88%
Trailing 12-Months
Company Description
Annovis Bio
Annovis Bio Inc is a United States based clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
---
07X Stock 12 Month Forecast
Average Price Target
€23.69
▲(185.45% Upside)
Technical Analysis
Bioxcel Therapeutics
―
Alzamend Neuro
―
SELLAS Life Sciences Group
―
Axsome Therapeutics
―
Annovis Bio
―
Best Analysts Covering 07X
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
-11.54%
reiterated a buy rating 4 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of -11.54% per trade.
---